Amphista Therapeutics
- Biotech or pharma, therapeutic R&D
At Amphista Therapeutics, we are focused on transforming the lives of patients with severe diseases, including cancer and neurodegenerative disorders, through the discovery of advanced, next generation targeted protein degradation (TPD) medicines. Amphista applies its proprietary Eclipsys™ platform to generate unique, sequentially bifunctional Targeted Glue® therapeutics with a differentiated mechanism and leading drug-like properties. Our portfolio offers the potential to deliver first- and/or best-in-class therapeutics with performance characteristics beyond the limitations of CRBN and VHL-based agents.
At BIO we are are seeking new partnerships focussed around our current portfolio of SMARCA2, TEAD, KRAS G12D and HDAC6 Targeted Glues® or matching your ligands with our proprietary Targeted Glue® degrader technology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}